Moneycontrol

Budget 2023Budget 2023
Register Now : Nifty Banker 3.0 | India's First Retail Index Traders Online Conference.
Budget 2023
Budget 2023
you are here: HomeNewsTrendsHealth

Bharat Biotech gets DCGI nod for intranasal vaccine booster trial

The booster dose trials of the intranasal vaccine will be conducted at nine different sites by Bharat Biotech -- the makers of Covaxin.

January 28, 2022 / 04:03 PM IST
Covaxin maker Bharat Biotech’s Chairman Krishna Ella and his wife and co-founder of the firm Suchitra Ella

Covaxin maker Bharat Biotech’s Chairman Krishna Ella and his wife and co-founder of the firm Suchitra Ella

The Drugs Controller General of India (DCGI) on January 28 granted permission to Bharat Biotech to start conducting booster dose trials for its intranasal coronavirus vaccine.

The approval has been granted to conduct phase-3 trials. The trials would evaluate the nasal vaccine for both the two-dose primary schedule and also to use as booster dose schedule, company sources told .

The trials will be conducted at nine different sites by Bharat Biotech -- the makers of Covaxin.

Earlier this month, in a bid to prevent the spread of coronavirus infection driven by its Omicron variant, India has started administering the precautionary dose of COVID-19 vaccine to healthcare and frontline workers and comorbid people aged 60 years and above.